Drug
Empagliflozin clinical trials
Also written Jardiance and BI 10773.
- studies test it
- 403
- open now
- 103
- in phase 3
- 90
- first study started
- 2007
Keep track of what changes. Save the empagliflozin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
402 studies that test it; most in 2024 (43); 1 more planned to start later
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 10 |
| 2010 | 15 |
| 2011 | 14 |
| 2012 | 4 |
| 2013 | 7 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 19 |
| 2017 | 32 |
| 2018 | 25 |
| 2019 | 19 |
| 2020 | 21 |
| 2021 | 30 |
| 2022 | 34 |
| 2023 | 35 |
| 2024 | 43 |
| 2025 | 43 |
| 2026 | 29 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 9
- Phase 1
- 87
- Phase 2
- 97
- Phase 3
- 90
- Phase 4
- 111
- No phase
- 32
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 132 · Other 271
Boehringer Ingelheim (93) · Humanis Saglık Anonim Sirketi (8) · Tanta University (8) · The University of Texas Health Science Center at San Antonio (8) · University Hospital, Basel, Switzerland (6) · Ain Shams University (6) · The University of Hong Kong (4) · Medanta, The Medicity, India (4)
Often tested with
Tested in the same studies.
Metformin (40) · Linagliptin (23) · Dapagliflozin (18) · Semaglutide (11) · Pioglitazone (11) · Sitagliptin (7) · Finerenone (6) · Canagliflozin (5)
Studies
Open first, then newest update. How each study uses empagliflozin is read from its arms, and is right about nine times in ten.
Testing it · 403
- Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE PreventionRecruitingPhase 3Insel Gruppe AG, University Hospital BernNCT06653738Written as Empagliflozin 10 MG
- Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis PatientsRecruitingPhase 2Chinese University of Hong KongNCT06483074Written as Empagliflozin 10 MG
- Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With ObesityRecruitingPhase 2VA Office of Research and DevelopmentNCT06745063Written as Empagliflozin
- EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)Not yet recruitingPhase 2Virginia Commonwealth UniversityNCT07883512Written as Empagliflozin
- Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart FailureRecruitingEarly Phase 1University of MinnesotaNCT06507657Written as empagliflozin
- Feasibility Trial for a Right Ventricular Failure Platform TrialRecruitingPhase 2University of AlbertaNCT06570473Written as Empagliflozin
- A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the BodyRecruitingPhase 1Boehringer IngelheimNCT07845630Written as Empagliflozin
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationPhase 4Baylor Research InstituteNCT07547878Written as Jardiance
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Empagliflozin
- Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid ArthritisNot yet recruitingPhase 2Al-Azhar UniversityNCT07864688Written as Empagliflozin
- Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's DiseaseNot yet recruitingPhase 2Wake Forest University Health SciencesNCT07756294Written as Empagliflozin
- Cardioprotective Effect of Empagliflozin in Breast Cancer PatientsNot yet recruitingPhase 3Tanta UniversityNCT07815808Written as Empagliflozin (EMPA)
- The GranStone TrialNot yet recruitingPhase 2/3Martin Blomberg JensenNCT07828002Written as empagliflozin (Jardiance) 25 mg
- A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health RecordRecruitingPhase 4Herlev and Gentofte HospitalNCT06642272Written as Empagliflozin 10 MG
- Empagliflozin in Patients With Cirrhosis and AscitesRecruitingPhase 2Yale UniversityNCT05726032Written as Empagliflozin 10 MG
- SGLT2i in Kidney StonesRecruitingEarly Phase 1University of ChicagoNCT07055282Written as Empagliflozin (Jardiance®)
- Neurovascular Effects of EmpagliflozinNot yet recruitingPhase 4Kanokwan BunsawatNCT07799441Written as Empagliflozin (EMPA)
- SGLT2 Inhibition With Empagliflozin in Fontan Circulatory FailureRecruitingPhase 3Subodh VermaNCT06955260Written as Empagliflozin 10 mg
- The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial FunctionRecruitingPhase 1/2Vanderbilt University Medical CenterNCT05972564Written as Empagliflozin 25 MG
- Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart FailureRecruitingPhase 3Christian SchulzeNCT07038356Written as Empagliflozin 10 MG Oral Tablet [Jardiance]
See all 403 studies that test empagliflozin →
Given in every arm · 11 — empagliflozin is usual care beside what is tested
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartRecruitingPhase 3Boehringer IngelheimNCT06935370Written as empagliflozin
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureRecruitingPhase 3Boehringer IngelheimNCT06424288Written as empagliflozin
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseRecruitingPhase 3Boehringer IngelheimNCT07064473Written as Empagliflozin
- A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)RecruitingPhase 3Colorado Prevention CenterNCT06024746Written as Empagliflozin
- QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyNot yet recruitingPhase 4Huijie ZhangNCT07775846Written as empagliflozin
- EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Active, not recruitingPhase 3Boehringer IngelheimNCT06531824Written as Empagliflozin
- Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With MetforminCompletedPhase 3CelltrionNCT06571591Written as Empagliflozin
- Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney DiseaseCompletedPhase 2Mostafa BahaaNCT05638880Written as Empagliflozin 10 MG
- Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 DrugsActive, not recruitingNot applicableNazarbayev UniversityNCT07303556Written as dapagliflozin, empagliflozin, metformin
- Effects of Linagliptin in Addition to Empagliflozin on Islet Cell PhysiologyCompletedPhase 4Profil Institut für Stoffwechselforschung GmbHNCT02401880Written as Empagliflozin
- Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT01301742Written as BI 10773
As the comparator · 16 — what is tested is compared with empagliflozin
- Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes MellitusRecruitingPhase 3EMSNCT05028140Written as EMPAGLIFLOZIN
- Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes MellitusRecruitingPhase 3EMSNCT04670666Written as EMPAGLIFLOZIN + LINAGLIPTIN
- Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.RecruitingPhase 3EMSNCT04602754Written as EMPAGLIFLOZIN
- Effectiveness of Weight Loss Methods on Lifespan for Metabolic SyndromeRecruitingPhase 4University Medical Center, KazakhstanNCT06410352Written as Semaglutide, Empagliflozin
- Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and DyslipidemiaNot yet recruitingPhase 3EMSNCT04603508Written as EMPAGLIFLOZIN
- Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal DiseaseActive, not recruitingPhase 4Yale UniversityNCT05671991Written as Empagliflozin 10 MG
- Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy VolunteersCompletedPhase 1Handok Inc.NCT07102719Written as Teneligliptin and Empagliflozin
- Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy VolunteersCompletedPhase 1Handok Inc.NCT06339788Written as Empagliflozin
- Canagliflozin in Patients With Acute Decompansted Heart FailureCompletedPhase 3October 6 UniversityNCT05364190Written as Empagliflozin
- Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and HypertensionWithdrawnPhase 3EMSNCT04970108Written as Empagliflozin + telmisartan
- Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and ObesityWithdrawnPhase 3Novo Nordisk A/SNCT05444153Written as Empagliflozin
- Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes MellitusCompletedPhase 3Novo Nordisk A/SNCT02863328Written as empagliflozin
- Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate HypertensionCompletedPhase 2SanofiNCT03462069Written as Empagliflozin
- Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With MetforminCompletedPhase 3Lexicon PharmaceuticalsNCT03351478Written as Empagliflozin
- A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart FailureTerminatedPhase 2Novartis PharmaceuticalsNCT03152552Written as Empagliflozin
- The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End ProductsWithdrawnPhase 4Northwell HealthNCT02768220Written as empagliflozin
Codes
What other systems call empagliflozin · ClinicalTrials.gg INT005994
- MeSH (NLM) C570240empagliflozinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) HDC1R2M35UEMPAGLIFLOZINConfirmed FDA, NLM, Wikidata
- RxNorm 1545653Confirmed FDA, Wikidata
- Wikidata Q5373824empagliflozinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C158136EmpagliflozinOne source FDA
- DrugBank DB09038One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C570240 | empagliflozin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | HDC1R2M35U | EMPAGLIFLOZIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1545653 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5373824 | empagliflozin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C158136 | Empagliflozin | One source FDA |
| DrugBank | DB09038 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.